Amended Current Report Filing (8-k/a)
May 14 2020 - 5:01PM
Edgar (US Regulatory)
0001551152
False
Common Stock, $0.01 Par Value
ABBV
0001551152
2020-05-07
2020-05-08
0001551152
us-gaap:CommonStockMember
exch:XNYS
2020-05-07
2020-05-08
0001551152
exch:XCHI
us-gaap:CommonStockMember
2020-05-07
2020-05-08
0001551152
abbv:Sec1.375SeniorNotesDue2024Member
exch:XNYS
2020-05-07
2020-05-08
0001551152
abbv:Sec0.750SeniorNotesDue2027Member
exch:XNYS
2020-05-07
2020-05-08
0001551152
abbv:Sec2.125SeniorNotesDue2028Member
exch:XNYS
2020-05-07
2020-05-08
0001551152
abbv:Sec1.250SeniorNotesDue2031Member
exch:XNYS
2020-05-07
2020-05-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(AMENDMENT NO. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 8, 2020
ABBVIE INC.
(Exact Name of Registrant as Specified
in its Charter)
_______________________________________________
Delaware
|
|
001-35565
|
|
32-0375147
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
_______________________________________________
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (847) 932-7900
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, $0.01 Par Value
|
|
ABBV
|
|
New York Stock Exchange
Chicago Stock Exchange
|
1.375% Senior Notes due 2024
|
|
ABBV24
|
|
New York Stock Exchange
|
0.750% Senior Notes due 2027
|
|
ABBV27
|
|
New York Stock Exchange
|
2.125% Senior Notes due 2028
|
|
ABBV28
|
|
New York Stock Exchange
|
1.250% Senior Notes due 2031
|
|
ABBV31
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.01.
|
Completion of Acquisition or Disposition of Assets.
|
On May 8, 2020, AbbVie Inc. (“AbbVie”)
filed with the Securities and Exchange Commission (“SEC”) a Current Report on Form 8-K (the “Initial Report”)
to report the completion of AbbVie’s acquisition of Allergan plc (“Allergan”).
Pursuant to the Transaction Agreement, dated as of June 25, 2019 (as amended on May 5, 2020), by and among AbbVie, Allergan and
Venice Subsidiary LLC, a Delaware limited liability company and a direct wholly-owned subsidiary of AbbVie (“Acquirer
Sub”), Acquirer Sub acquired Allergan pursuant to a scheme of arrangement (“Scheme”)
under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Act”) and a capital reduction under Sections 84 to
86 of the Act (the “Acquisition”). As a result of the Scheme, Allergan became a wholly-owned subsidiary of AbbVie.
This
Current Report on Form 8-K/A amends the Initial Report to include the following historical financial statements and pro forma financial
information required by Item 9.01 of Form 8-K that were previously omitted from the Initial Report as permitted by Item 9.01(a)(4):
(a) Allergan’s consolidated financial statements and financial statement schedule as
of December 31, 2019 and 2018 and for each of the years in the three-year period ended December 31, 2019, the related notes, the
related Report of Independent Registered Public Accounting Firm thereon and management’s report on internal control
over financial reporting for the year ended December 31, 2019, which
are incorporated by reference as Exhibit 99.1 hereto, (b) Allergan’s unaudited consolidated financial statements as of March
31, 2020 and for the three months ended March 31, 2020 and March 31, 2019 and the related notes, which are incorporated
by reference as Exhibit 99.2 hereto, and (c) the unaudited pro forma condensed combined financial information of AbbVie
giving effect to the Acquisition (the “pro forma financial information”), which includes the unaudited pro forma condensed
combined balance sheet as of March 31, 2020, the unaudited pro forma condensed combined statements of earnings for the year ended
December 31, 2019 and for the three months ended March 31, 2020 and the related notes, and which is filed herewith as Exhibit 99.3
and included herein.
The pro forma
financial information included in this Current Report on Form 8-K/A has been presented for informational purposes only and is not
necessarily indicative of the combined financial position or results of operations that would have been realized had the Acquisition
occurred as of the dates indicated, nor is it meant to be indicative of any anticipated combined financial position or future results
of operations that AbbVie will experience after the Acquisition.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(a) Financial Statements of Businesses
Acquired.
Allergan’s
consolidated financial statements and financial statement schedule as of December 31, 2019 and 2018 and for each of the years in
the three-year period ended December 31, 2019, the related notes, the related Report of Independent Registered Public Accounting
Firm thereon and management’s report on internal control over financial
reporting for the year ended December 31, 2019 are incorporated by reference
as Exhibit 99.1 hereto.
Allergan’s
unaudited consolidated financial statements as of March 31, 2020 and for the three months ended March 31, 2020 and March 31, 2019
and the related notes are incorporated by reference as
Exhibit 99.2 hereto.
(b) Pro Forma Financial Information.
The unaudited pro forma condensed combined
financial information of AbbVie, giving effect to the acquisition of Allergan, which includes the unaudited pro forma condensed
combined balance sheet as of March 31, 2020, the unaudited pro forma condensed combined statements of earnings for the year ended
December 31, 2019 and for the three months ended March 31, 2020 and the related notes, is filed herewith as Exhibit 99.3 and included
herein.
(d) Exhibits
The following exhibits are included as part of this
Current Report on Form 8-K:
Exhibit
No.
|
|
Description
|
|
|
|
23.1
|
|
Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of Allergan.
|
|
|
|
99.1
|
|
Allergan’s consolidated financial statements and financial statement schedule as of December 31, 2019 and 2018 and for each of the years in the three-year period ended December 31, 2019, the related notes, the related Report of Independent Registered Public Accounting Firm thereon and management’s report on internal control over financial reporting for the year ended December 31, 2019 (incorporated by reference to Allergan’s Annual Report on Form 10-K (File No. 001-36867) for the year ended December 31, 2019, as filed with the SEC on February 18, 2020).
|
|
|
|
99.2
|
|
Allergan’s unaudited consolidated financial statements as of March 31, 2020 and for
the three months ended March 31, 2020 and March 31, 2019 and the related notes (incorporated by reference to Allergan’s
Quarterly Report on Form 10-Q (File No. 001-36867) for the three months ended March 31, 2020, as filed with the SEC on May
7, 2020).
|
|
|
|
99.3
|
|
The unaudited pro forma condensed combined
financial information of AbbVie, giving effect to the acquisition of Allergan, which includes the unaudited pro forma condensed
combined balance sheet as of March 31, 2020, the unaudited pro forma condensed combined statements of earnings for the year
ended December 31, 2019 and for the three months ended March 31, 2020 and the related notes.
|
|
|
|
104
|
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ABBVIE INC.
|
|
|
Date: May 14, 2020
|
By:
|
/s/ Robert A. Michael
|
|
|
Robert A. Michael
|
|
|
Executive Vice President, Chief Financial Officer
|
Common Stock, $0.01 Par Value
|
ABBV
|
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024